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Introduction: The aim of this study is to assess factors influencing 
survival in patients with bronchial carcinoids (BCs).
Methods: A retrospective review of our surgical database of patients 
operated for primary lung cancer with a final histologic diagnosis of 
BC in the period from January 1, 1995 to December 31, 2010 was 
carried out.
Results: There were 126 patients (74 women): 83 had a typical car-
cinoid and 43 an atypical one (AC). All patients received a radical 
resection; systematic lymphadenectomy was accomplished in 120. 
Lymph nodal metastases were observed in 26 cases (12 N2) and were 
more frequent in ACs (p = 0.009). Twelve patients received adju-
vant therapy (chemo/radio/biological). Distant metastases (DM) and 
local tumor recurrence occurred in 28 (22%) and 8 (6.3%) cases, 
respectively: DM were more frequent in ACs (p = 0.0001) and in 
N2 patients (p = 0.0001). Smoke, atypical histology, lymph nodal 
metastases, and high cellular proliferative index demonstrated to be 
statistically negative prognostic factors.
Conclusion: Even if characterized by an indolent behavior, BCs may 
spread to lymph node or distant or present with local recurrence. 
Amid all prognostic factors, the presence of DM demonstrated to be 
the strongest negative one.
Key Words: Typical carcinoid, Atypical carcinoid, Lymph nodal 
metastases, Neuroendocrine tumors, Distant metastases, Prognostic 
factors.
(J Thorac Oncol. 2013;8: 1282-1288)
Bronchial carcinoids (BCs) belong to the family of pul-monary neuroendocrine (NE) tumors, which include a 
spectrum of neoplasms that span from the low-grade typi-
cal carcinoid (TC) and intermediate grade atypical carcinoid 
(AC) to the high-grade large-cell NE carcinoma (LCNC) 
and small-cell carcinoma.1 NE proliferation may also be 
subdivided into a spectrum of preinvasive lesions, from NE 
cell hyperplasia to tumorlets2 but, as this subdivision is not 
yet completely understood, its real clinical significance is still 
matter of debate.3,4
BCs are considered rare tumors with an annual inci-
dence comprising between 2.3 and 2.8 cases per 1 million 
people5; they include 20% to 25% of all carcinoid tumors6 but 
account to only 0.4% to 3% of all primary lung cancers.7,8 
Nearly 10% of BCs are ACs; thus ACs add up to only 0.1% to 
0.2% of all malignant lung neoplasms.6
TCs rarely metastasize and manifest a 5-year survival 
rate ranging between 97% and 100%,9,10 whereas patients 
with AC have a greater tendency to present with lymph nodal 
metastases and have a 5-year survival rate varying from 25% 
to 70%.11,12
In a previous publication we discussed the surgical 
management of BCs and long-term survival,13 emphasizing 
the role of the histological differentiation and lymph nodal 
metastases as factors strongly influencing survival. Through 
the present article we aim to analyze our recent experience 
regarding multimodal treatment of BCs, pointing out the role 
of clinical and pathological variables as factors improving 
long-term survival.
MATERIALS AND METHODS
We carried out a retrospective review of our surgical 
oncological database, selecting patients operated for BCs 
between January 1995 and December 2010 among all with a 
primary lung cancer.
The following were the exams included in the preop-
erative assessment of each patient: standard chest radiograph, 
electrocardiogram, thoracic, brain, and upper-abdominal com-
puted tomography scan, bronchoscopy, and lung functional 
tests. Perfusional lung scanning and echocardiography where 
requested when a major surgical procedure was planned. 
Positron emission tomography scan has been available in our 
hospital since 2000.
According to the tumor location definition reported in 
the literature(8),all tumors directly visualized at bronchos-
copy or in association with lung atelectasis and/or obstructive 
pneumonia were classified as central, whereas the peripheral 
lesions were those not observed at bronchoscopy. Usually, in 
case of central lesions, bronchoscopy was successful in achiev-
ing a preoperative diagnosis (either carcinoid/carcinoma with 
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NE features or common non–small-cell lung cancer) whereas, 
in case of peripheral ones, fine-needle aspiration biopsy was 
often used.
All patients underwent surgical resection through a pos-
terolateral or anterolateral thoracotomy; systematic lymphad-
enectomy was performed in all cases but six.
The extent of the surgical resection was planned on the 
basis of tumor local growth and condition of lung parenchyma 
and, whenever feasible, bronchial sleeve resections were per-
formed. Bronchial margins frozen section was performed in 
all cases of bronchoplastic procedures. Sublobar resections 
(especially segmental ones) were performed when patients 
were functionally at high risk for lobectomy.
The definitive histologic diagnosis of bronchial car-
cinoid (and its histologic differentiation in TC or AC) was 
confirmed by our pathologists (SA and LD), experts in NE 
lung neoplasms, by reviewing all histologic sections accord-
ing to the Travis’s histologic guidelines for BC diagnosis.14 
Immunohistochemical staining using anti–Ki-67 antibody 
(DAKO, Glostrup, Denmark) was carried out, and the Ki-67 
labeling index (expressed as percentage of positive cells) was 
calculated in 110 patients (79 TCs and 31 ACs). All the tumors 
were staged using the 7th tumor node metasis staging system 
for malignant lung tumors.15,16
Statistical Analysis
Cumulative survival rates were calculated by the 
Kaplan–Meier method, using the date of surgical resection as 
the starting point and the date of death or the last follow-up 
date as the endpoint. Statistical differences between survivals 
were calculated with the log-rank test. The Cox proportional 
hazards model was used in the multivariate analysis to inves-
tigate the relative importance of different prognostic factors. 
Competing-risks regression models were used to explore the 
role of variables significantly affecting the development of 
distant metastases (DM) according to the method of Fine and 
Gray, taking into account death as a competing event. Hazard 
ratios (Hrs) for DM with 95% confidence intervals (95%CIs) 
were also calculated. All the statistical analyses were con-
ducted using the STATA 11.2 software (StataCorp LP, College 
Station, TX).
RESULTS
Patients Characteristics
There were 126 BCs available for analysis (74 women; 
58.7%) and the mean age was 60 years (range, 15–82 years). 
Eighty-three patients (65.9%) were affected by TC, 43 by ACs. 
The smokers group (56 patients, 44.4%) were more frequent 
in ACs (26 patients, p = 0.01).
Clinical Presentation and Methods of Diagnosis
In 73 patients (58%; 54 TCs), the most common clinical 
symptoms observed were hemoptysis (n = 27), cough (18), chest 
pain (9), fever (4), dyspnea (4) and pneumonia (16). Clinical 
symptoms at presentation were more frequent in TCs (p = 0.04).
A total of nine paraneoplastic syndromes were observed 
(3 acromegaly, 2 encephalitis, 1 Cushing’s syndrome, 2 
flushing syndromes, and 1 myasthenia gravis) but we did not 
come across any carcinoid syndrome.
Sixty-six BCs were located in the right lung (62%) and 
60 in the left one. Peripherally located tumors were present in 
69 patients (54.8%; 33 ACs) and occurred more frequently in 
the AC group (p = 0.0001).
Fifty-seven BCs were centrally located tumors: three 
were located in the main bronchus (2 in the right side), 10 in 
the intermediate, in 41 cases in the lobar, three in a segmental 
bronchus. In all of them bronchoscopy was effective in tumor 
detection.
A preoperative cyto-histologic diagnosis of cancer was 
obtained in 53 patients (95%). The cyto-histologic confirma-
tion of carcinoid or that of a tumor presenting with NE features, 
was obtained in 32 of them (57.1%). No episodes of dangerous 
bleeding were observed during the bioptic maneuvers.
Transthoracic fine-needle aspiration (TTNA) biopsy 
was performed in 56 peripheral tumors in which the broncho-
scopic evaluation did not show any endoluminal lesion. TTNA 
showed effective results in 51 tumors (91%). A preoperative 
positron emission tomography scan was performed in 45 BCs; 
it was positive in six ACs and 27 TCs, with a mean standard-
ized uptake value value of 3.1 ± 0, and negative in the others.
111In-DTPA-Octreotide Scintigraphy (Octreoscan) was 
not routinely performed in all patients with NE tumor because 
of the high costs and difficulty to provide a quick access to 
patients. This was deemed as unethical to us because patients 
would have had to wait for a long time before surgery. Thus, 
only 14 patients (9 TCs) were submitted to a preoperative 
Octreoscan, which showed positive results in 13.
Surgical Treatment
A radical surgical resection (r0) was accomplished in 
all patients. Lobectomy was performed in 94 cases (74.6%), 
sleeve lobectomy in 4 (2 left superior, 1 right superior, and 1 
right inferior), wedge/segmental resection in 14, bilobectomy 
in 11, and pneumonectomy in three (2 ACs). In particular 
lobectomy was performed in 58 TCs and 36 Acs, and bilobec-
tomy in nine TCs and two ACs.
According to the European Society of Thoracic 
Surgeons (ESTS) recommendations for intraoperative lymph 
node staging17 (removal of at least 6 lymph nodes from hilar 
and mediastinal stations), systematic nodal dissection was 
performed in 120 cases (95%). The median number of dis-
sected nodal stations was 4 (range, 2–7) including at least two 
to three lymph nodes, for each one.
No postoperative mortality was registered. Postoperative 
complications included atrial fibrillation in one pneumonec-
tomy case, pneumonia in two, severe respiratory insufficiency 
in four (1 patient required prolonged intensive care unit recov-
ery), STrOKE and prolonged pleural effusion in one case each.
Pathology
The mean tumor size was 2.8 ± 1.7 cm (range, 0.6–11). 
ACs were bigger in size than TCs (mean ACs size: 3.3 ± 2.1 cm, 
versus mean TCs size: 2.5 ± 1.3 cm; p = 0.04).
Twenty-six patients (11 TCs and 15 ACs) had a lymph 
nodal involvement (N+): 14 cases were N1, 12 were N2. 
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ACs had an increased risk of 2.3 times to present with 
lymph nodal metastases when compared with TCs (p = 
0.009). In particular, skip metastases were observed in 10 
N2 patients (83.3%; 8 ACs). Table 1 summarizes tumor 
stages according to the 7th TNM staging system for malig-
nant lung tumors.
One hundred ten tumors were tested with anti–Ki-67 
antibodies, 41 of these showed a Ki-67 more than 6.0%. The 
evidence of an elevated Ki-67 percentage was significantly 
more frequent within ACs (p = 0.03).
Fourteen N+ patients presented with Ki-67 more than 
6.0%: those biologically aggressive neoplasms were at higher 
risk to develop lymph nodal metastases (Hr 1.99; 95% CI: 
1.23–3.22; p = 0.018). TCs were statistically more frequently 
detected in an early stage rather than ACs (p = 0.003).
Fifty-two patients presented a tumor with dimension 
greater than 3.0 cm, of which 13 (25%) had positive nodes (3 
N1 and 10 N2), whereas other 13 patients (19%) with lesion 
inferior to 3 cm in size had nodal involvement (11 N1 and 2 
N2) hence demonstrating that the tumor size is not correlated 
with N+ disease.
Twelve BCs (6 ACs) underwent an adjuvant treatment: 
five patients received cisplatin–etoposide chemotherapy 
whereas four received a long-acting somatostatin analogue; 
three patients were granted to radiotherapy.
Survival, DM, and Local Recurrence
The median follow-up was 60 months (range, 1.68–
183.6 months). At the end of the follow-up 30 patients (22 
ACs) died. Five- and 10-year survival rates of the overall BC 
population are reported in Figure 1.
The overall survival was strongly influenced by tumor 
histology (p = 0.0001; Fig. 2) and by the presence or absence 
of lymph nodal metastases (p = 0.0001; Fig. 3). Twenty-
eight patients (22.2%; 20 ACs) developed DM during the 
follow-up period and DM were significantly more frequent in 
ACs (p = 0.0001) and in BCs with a stage greater than IB 
(p = 0.003). A single metastasis was observed in 22 patients, 
and the most common metastatic sites were brain (n = 10), liver 
(n = 7), and bone (n = 5). Six patients developed diffuse mul-
tiple metastases.
In the group of patients with a single metastasis, five 
received chemotherapy and two a long-acting somatostatin 
analogue, five radiotherapy, and three a combined radio/che-
motherapy treatment. Seven patients received supportive care 
only. No patient with a single brain metastasis received sur-
gery, because the lesion was not deemed radically resectable 
by our neurosurgeons.
Loco-regional (Lr) tumor recurrences developed in 
eight patients (6.3%; 5 ACs); there was a trend toward a 
higher risk to develop Lr in ACs, even if our data did not 
reach a statistical significance because of the small number 
of cases.
TABLE 1.  Five- and 10-year Survival Rates According to the 
BC Tumor Node Metastasis stage
Stage BCs TCs ACs
5-Yr 
Survival 
(%)
10-Yr 
Survival 
(%)
IA 64 46 18 85 75
IB 26 20 6 95 80
IIA 13 9 4 80 40
IIB(4 T3N0) 5 1 4 100 65
IIIA 14 5 9 25 20
IIIB 2 0 2 50 0
IV 2 2 0 — —
Total 126 83 42
BC, bronchial carcinoid; AC, atypical carcinoid; TC, typical carcinoid.
FIGURE 1.  Bronchial carcinoid tumors: overall survival 
curve. Five- and 10-year survival rates were 82% and 68%, 
respectively.
FIGURE 2.  Survival according to histologic subtypes of 
bronchial carcinoids. Typical carcinoids 5-, 10-year survival 
rates were: 91% and 86%, respectively, whereas those for 
atypical carcinoids were: 68.5% and 43%, respectively.
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Overall disease-free interval (DFI) was 4.78 ± 3.91 
years (range, 0.14–11.75 years; median: 2.60 years). Taking 
in count DM, DFI was 3.47 ± 3.27 years (range, 0.14–11.75 
years; median: 2.15 years). In case of Lr, DFI was 9.74 ± 2.35 
years (range, 6.68–11.35 years; median: 10.01 years).
Because of the intrinsic Lr characteristics (more indo-
lent than DM, and with a longer DFI), surgery was offered 
only to fit patients (3), whereas two received radiotherapy, 
one received combined chemo and radiotherapy along with 
long-acting octreotide, and two received supportive care, only. 
These differences in treatment depended on the lack of an uni-
vocal guideline and on the different oncological approaches 
taken during the study period.
The presence of lymph nodal metastases has statisti-
cally proved to be the greatest negative prognostic factor 
for the development of DM (Hr 7.36; 95% CI: 3.33–16.24; 
p = 0.0001) but, surprisingly, we observed that an adjuvant 
treatment in N+ patients (chemotherapy, radiotherapy, or bio-
logical treatment with somatostatin analogue) did not reduce 
the risk of developing DM (Hr 2.78; 95% CI: 1.11–6.91; 
p = 0.03).
Prognostic Factors
The univariate model highlighted that smoke, atypical 
histology, the presence of lymph nodal metastases, and a per-
centage of Ki-67 greater than 6.0 were all negative prognos-
tic factors (Table 2). The multivariate model evidenced that 
the atypical tumor histology (Hr 3.14; 95% CI: 1.26–7.83; 
p = 0.01) and the presence of lymph nodal involvement (Hr 
4.60; 95% CI: 1.74–12.20; p = 0.002) resulted independent 
negative prognostic factors (Table 2). The results of the 
competing-risks analyses on potential predictors of DM are 
reported in Table 3.
Our results at the univariate model proved that smoke 
(p = 0.001), atypical histology (p = 0.0001), Ki67 more than 
6.0% (p = 0.015), lymph nodal metastases (p =0.0001), and 
adjuvant treatment (p = 0.03) are associated with an increased 
risk of DM development, though the anatomical resection 
proved to be a protective factor against it (p = 0.0001). The 
DM development demonstrated to be the strongest negative 
independent prognostic factor (Hr 10.97; 95% CI: 4.98–
24.134; p = 0.0001).
DISCUSSION
The management of BCs has always been based on 
preconceptions derived from dated observations. Although 
for a long time BCs were considered benign lesions for the 
indolent behavior shown, nowadays they are considered 
malignant tumors because of the potential local invasive-
ness, lymph nodal metastases, and/or local or distant tumor 
relapses (Fig. 4).
As BCs may present in an aggressive form or in 
an advanced stage or even with metastases, the clinical 
FIGURE 3.  Survival according to the presence of N tumor 
involvement. N, lymph nodal involvement.
TABLE 2.  Bronchial Carcinoids
Univariate Model Multivariate Model
Bronchial Carcinoids p HR 95% CI p HR 95% CI
Cox Proportional Hazards Model
Male sex 0.42 1.34 0.66–2.75 0.65 1.21 0.53–2.77
Atypical histology 0.0001 5.33 2.37–11.99 0.01 3.14 1.26–7.83
Smoke 0.046 2.05 1.18–4.28 0.19 1.72 0.77–3.86
Peripherical location 0.20 1.63 0.77–3.43 0.91 1.05 0.44–2.49
Symptoms 0.24 0.65 0.32–1.33 0.67 0.84 0.37–1.87
right side 0.68 1.16 0.56–2.40 0.31 1.58 0.65–3.83
Anatomical resection 0.73 0.27 0.09–5.21 0.42 0.41 0.04–3.59
KI67% ≥ 6.0% 0.045 2.08 1.02–4.27 0.68 1.18 0.52–2.70
Lymph nodal metastases 0.0001 6.13 2.76–13.58 0.002 4.60 1.74–12.20
Adjuvant therapy 0.06 2.53 0.96–6.66 0.69 1.23 0.43–3.52
Variables influencing survival. Endpoint: death.
CI, confidence interval; Hr, hazard ratio.
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management of such particular cases is intricate because of 
the lack of randomized clinical trials. Presently, universally 
accepted guidelines do not exist.
The search for prognostic factors that might somehow 
predict a more aggressive biological behavior of BCs has been 
the aim of some recent articles.18–20
Ours is a single-center retrospective study on multi-
modal BC management. We started investigating BCs in the 
late 1970s, and in a previous publication13 we reported our his-
torical BC series from 1977 to 2000. By then we had already 
identified the role that atypical histology and the presence of 
lymph nodal involvement play as independent negative prog-
nostic factors.
In the course of time, the development of diagnostic and 
therapeutic tools changed both the approach to BCs and the 
results previously obtained, except for some outcomes that 
still stand confirmed. In fact, in this article we detected that 
in the univariate model smoke, the atypical histology, a Ki-67 
more than 6.0% and the presence of lymph nodal involvement, 
were significant adverse prognostic factors but, in the mul-
tivariate setting only atypical histology and the lymph node 
metastases were confirmed to be independent negative prog-
nostic factors.
Whether or not to consider smoke as a risk factor for 
developing BCs is still matter of debate. Some studies point 
out such tendency, especially concerning the development of 
ACs13,21 but, contrariwise, other authors do not emphasize a 
strict correlation between BC development and tobacco use, 
observing that in BCs there is not a significant difference in 
terms of survival rates between smokers and nonsmokers.9,12 
We did observe a relation between smoke and a high risk to 
develop DM: to our knowledge this is the first time such a 
finding has been observed.
Compared with TCs, ACs show a more aggressive bio-
logical behavior for the reason that they are characterized by 
a greater tendency to develop lymph nodal metastases and 
a higher recurrence rate.5,12,22 As a result, the 5- to 10- and 
15-year survival rates of ACs (with or without lymph nodal 
metastases) are worse than those of TCs.
Perhaps because in the past most authors did not per-
form a systematic lymphadenectomy, the prognostic role of 
lymph nodal involvement in BCs has been tackled only by few 
studies. A statistically significant difference in nodal involve-
ment between TCs and ACs was observed both in our previ-
ous article13 as well as in a more recent multicentric Spanish 
study.23 Although a routinely systematic lymphadenectomy 
was not performed in both series, nodal involvement was con-
firmed to be a negative prognostic factor. In a study consisting 
of 163 BCs treated with a formal lung resection and a radi-
cal mediastinal lymphadenectomy, Cardillo and associates12 
obtained the same outcome.
regarding our study, the typical surgical treatment of 
BCs consisted of an anatomic lung resection plus a system-
atic hilar and mediastinal lymphadenectomy, whereas wedge 
resections were offered only to patients with poor respiratory 
reserve.FIGURE 4.  Cumulative incidence of tumor relapses.
TABLE 3.  Bronchial Carcinoids
Univariate Model Multivariate Model
Bronchial Carcinoids p HR 95% CI p HR 95% CI
Competing-Risks Regression
Male sex 0.25 1.56 0.74–3.30
Atypical histology 0.0001 4.64 2.04–10.58 0.017 5.36 1.34–21.37
Smoke 0.001 2.95 1.29–6.76 0.005 5.52 1.68–18.06
Peripherical location 0.55 1.25 0.59–2.65
Symptoms 0.39 0.72 0.34–1.53
right side 0.79 0.90 0.43–1.91
Anatomical resection 0.0001 0.27 0.09–5.21
KI67% ≥ 6.0% 0.015 2.52 1.20–5.29
Lymph nodal metastases 0.0001 7.36 3.33–16.24 0.0001 15.47 4.39–54.48
Adjuvant therapy 0.03 2.78 1.11–6.91
Variables influencing distant metastases. Endpoint: distant metastases observation; death from any cause as competing event.
CI, confidence interval; Hr, hazard ratio.
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Moreover, by using the competing-risks regression 
models, we demonstrated that both the atypical histology and 
the presence of lymph nodal metastases are associated with 
a significantly higher risk of developing DM. Atypical his-
tology, presence of lymph nodal metastases, and high cellu-
lar proliferative activity seem to characterize a tumor with a 
highly aggressive biological behavior.
Ki67 (Mib 1) is a nuclear antigen expressed in prolif-
erating cells, evidently also detectable in BCs.24,25 Often, a 
strong expression of Ki-67 has been associated with an unfa-
vorable clinical outcome,18,26 and its fundamental prognostic 
implication was demonstrated also in gastroentero-pancreatic 
endocrine tumors27: this variable was thus included in the 
recent classification system of these neoplasms. In our experi-
ence, an expression of Ki-67 greater than 6.0% identifies an 
aggressive tumor with a high risk of lymph nodal involvement 
and possible tumor relapse.
An adjuvant chemotherapic treatment in aggressive BCs 
is indicated by evaluating several prognostic/clinical vari-
ables; further prospective studies might confirm Ki-67 utility 
to start off adjuvant therapy in patients with a high expression 
of this index, as actually occurs in gastroentero-pancreatic NE 
neoplasms.28,29
Our statistical analysis provides evidence that perform-
ing a non-anatomic surgical resection was related to a higher 
risk of developing DM. This result diverges with the conclu-
sions of a recent article by Yendamuri and associates,30 which 
contrawise stated that the extent of surgical resection is not a 
survival predictor, especially in the case of TCs.
As previously mentioned, our surgical policy is differ-
ent. We are convinced that performing wedge resections, even 
in case of a TC, is an inappropriate oncological procedure for 
the following reasons: (1) BCs should be considered malignant 
neoplasms and they should be treated as such; an anatomical 
surgical procedure has to be preferred to a wedge resection, 
and whenever there is an opportunity to spare lung paren-
chyma, a bronchial sleeve resection should be performed; (2) 
increased risk of not respecting safe resection margins; (3) 
high probability of missing eventual N1 lymph nodes.
In our series, DM occurred in 28 patients and were sta-
tistically more frequent in ACs. The indolent behavior of BCs 
has led several authors8,13 to suggest a long-term surveillance 
(at least 20 years).
Our data bring into evidence that the mean DFI for 
patients with DM was surprisingly short. DFI seems not to 
be influenced by an eventual adjuvant treatment, even if this 
statement is biased by the intrinsic limitations of our study. On 
the one hand, this seems to confirm that BCs do not act like 
other primary lung cancers and, on the other, that an effec-
tive postoperative treatment has not yet been developed. In 
fact, not more than 30% of cases are responsive to adjuvant 
chemotherapy treatments,31,32 (usually a small-cell lung cancer 
schedule) with similar rates for TCs and ACs; in case of para-
neoplastic syndrome, the use of a biological therapy such as 
α-interferon, with or without somatostatin analogue, seems to 
have a palliative effect although its antitumoral efficacy, even 
if sometimes reported,33,34 has been not yet widely accepted 
to date. Taking into consideration the advanced forms of BCs 
alone, encouraging results have been achieved by new che-
motherapy regimens with temozolamide35 or everolimus,36 but 
multicentric clinical trials need to confirm these preliminary 
results.
Our study has the limitation of intrinsic bias because 
of: (1) it is a retrospective monocentric series; (2) long time 
of observation; and (3) diverse adjuvant chemotherapeutic 
schedules have been used during these years.
Anyhow, the number of patients included is high even 
for a single center, and this represents a point of strength of 
this study, making its conclusions authoritative.
In conclusion, BCs are rare malignant tumors of the lung 
in which surgery, when practicable, remains the cornerstone 
of treatment; to prevent the risk of potential tumor relapse, 
an anatomic resection with a systematic lymphadenectomy 
seems most effective.
Though we demonstrated that both the atypical histol-
ogy and the presence of lymph nodal metastases were inde-
pendent negative prognostic factors, we also observed how 
the strongest one was DM occurrence, which dramatically 
reduced the overall survival of patients.
The lack of knowledge in the treatment of advanced 
stages, which stems from the rarity of these tumors, makes it 
crucial and necessary for all physicians involved in BC man-
agement (surgeons, oncologists, radiotherapists, endocrinol-
ogists, and pulmonologists) to join in a global effort toward 
finding more approaches for the treatment of BCs.
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